Get the Stockscreener App
351.02
1.29%
-4.58
Pre-market:
348.11
-2.91
-0.83%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $351.02, with a volume of 2.26M.
It is down -1.29% in the last 24 hours and down -6.50% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$355.60
Open:
$357.46
24h Volume:
2.26M
Relative Volume:
0.80
Market Cap:
$189.22B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
24.66
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
+0.89%
1M Performance:
-6.50%
6M Performance:
+20.99%
1Y Performance:
+24.74%
1-Day Range:
$349.75
$357.46
1-Week Range:
$335.06
$359.44
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
351.02 | 189.22B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Kelsey Financial LLC Makes New $7.13 Million Investment in Amgen Inc. $AMGN - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $527.74 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Robeco Institutional Asset Management B.V. Increases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by KG&L Capital Management LLC - MarketBeat
Curtis Advisory Group Adds Amgen Shares to Portfolio - National Today
Factory Mutual Insurance Trims Amgen Stake - National Today
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Clarity Wealth Advisors LLC Invests $3.91 Million in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Is It Time To Revisit Amgen (AMGN) After The Recent 4.6% Share Price Pullback - simplywall.st
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer | PharmExec - Pharmaceutical Executive
Amgen’s FORWARD II Gout Study: What a Less Frequent Krystexxa Schedule Could Mean for Investors - TipRanks
Amgen-Backed DLL3 Combo Trial Could Be A Game Changer For Zai Lab (ZLAB) - simplywall.st
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again - Yahoo! Finance Canada
Amgen’s lung cancer drug tarlatamab wins China approval - WTAQ
Amgen (NASDAQ:AMGN) Price Target Raised to $326.00 - MarketBeat
Amgen’s Tarlatamab Approved in China - Pharmaceutical Executive
NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap - Barchart
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart
OFI Invest Asset Management Increases Stake in Amgen - National Today
OFI Invest Asset Management Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Prime Capital Investment Advisors LLC Has $6.32 Million Stake in Amgen Inc. $AMGN - MarketBeat
Encompass Wealth Advisors Trims Amgen Stake by Over 50% - National Today
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033 - GlobeNewswire Inc.
Amgen's lung cancer drug tarlatamab wins China approval - Reuters
Encompass Wealth Advisors LLC Sells 3,010 Shares of Amgen Inc. $AMGN - MarketBeat
Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now? - Yahoo Finance
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
What Amgen (AMGN)'s TEPEZZA On‑Body Injector Phase 3 Results Mean For Shareholders - simplywall.st
Lobbying Update: $50,000 of TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Guggenheim Adjusts Amgen (AMGN) Price Target to $351, Maintains - GuruFocus
Investors heavily search Amgen Inc. (AMGN): Here is what you need to know - MSN
Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs (NASDAQ:AMGN) - Seeking Alpha
Guggenheim Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $351 - Moomoo
Guggenheim raises Amgen stock price target to $351 on product mix - Investing.com Canada
Amgen (AMGN) Stock: GLP-1 Drug MariTide Drives Analyst Optimism - CoinCentral
We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play. - Barron's
Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $350 - Moomoo
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha
Truist raises Amgen stock price target to $325 on revenue outlook - Investing.com
Amgen’s Tepezza On Body Injector Data Tests Thyroid Eye Disease Moat - simplywall.st
Is Amgen Stock Poised For A Rally? - Trefis
Cantor Fitzgerald maintains Amgen stock rating ahead of earnings - Investing.com
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Boston Scientific (BSX) - The Globe and Mail
Amgen releases positive topline results from phase 3 trial of teprotumumab-trbw (TEPEZZA) - Ophthalmology Times
BIP Wealth LLC Boosts Amgen Stake by Over 800% - National Today
BIP Wealth LLC Acquires 8,785 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition - Yahoo Finance
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.18%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):